Catalent Completes $350-Million Offering
Catalent Pharma Solutions, Inc. recently announced the successful completion of its $350-million offering of 7.875% Senior Notes due 2018, issued at par. Catalent has used a portion of the net proceeds from this offering to fund a portion of its tender offer for outstanding 9.5%/10.25% Senior PIK-election Notes due 2015, including related fees and expenses, and expects to use the remaining net proceeds to finance any additional purchases pursuant to the tender offer and any excess for general corporate purposes, which may include repayment of indebtedness.
The Notes, which mature October 15, 2018, were offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and to non-US persons in accordance with Regulation S of the Securities Act. The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the US or to, or for the benefit of, US persons absent registration under, or an applicable exemption from, the registration requirements of the Securities Act and applicable state securities laws.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. For more information, visit www.catalent.com.
Total Page Views: 1052
